The additive effect of latanoprost 0.005% in patients on maximally tolerated medical therapy

Clinical Eye and Vision Care

Volumn 9, Issue 4, 1997, Pages 189-196

  Strier, Shari E ^a,b  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Glaucoma; IOP; Latanoprost; Maximum medical therapy; Pilocarpine

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETAXOLOL; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; METIPRANOLOL; PILOCARPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG POTENTIATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; MAXIMUM PERMISSIBLE DOSE; NEGRO; STATISTICAL ANALYSIS;

EID: 0031445216     PISSN: 09534431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-4431(97)10015-7     Document Type: Article

References (17)

1. 2α analogue, after topical application in normal and ocular hypertensive eyes. Arch Ophthalmol 1993;111:1351-1358.
2. 2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988;105:30-34.
3. Toris CB, Camras CB, Yablonski ME et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997;41:S69-S75.
4. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41:S105-S110.
5. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41:S129-S138.
6. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41:S125-S128.
7. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997;41:S1-S14.
8. Rulo AH, Greve EL, Geijssen HC et al. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103:1276-1282.
9. Greve EL, Rulo AH, Drance SM et al. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol 1997;41:S89-S92.
10. Racz P, Ruzsonyi MR, Nagy ZT et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-273.
11. Hoyng PFJ, Rulo A, Greve E et al. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthal 1997;41:S93-S98.
12. Alm A, Widengard I, Kjellgren D et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16.
13. Fristrom B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. Arch Ophthalmol 1993;111:662-665.
14. Bartlett J, Jaanus S. Clinical ocular pharmacology, 3rd edn. Boston: Butterworths, 1995.
15. Camras CB, Alm A, Watson P et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996;103:1916-1924.
16. 2α. Arch Opthalmol 1987;105:1112-1116.
17. Lindsey JD, Kashiwagi K, Kashiwagi F et al. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol 1997;41:S53-S59.